肿瘤第一线 · 学术知识传播

订阅

MedSci主页 / 所有栏目 / 肿瘤第一线 · 学术知识传播

重组逆转录病毒质粒pLNCX/iNOS的构建

2021-11-23 MedSci原创 MedSci原创

其他威廉亚洲官网 阅读

构建含一氧化氮合酶（ iNOS）基因的重组逆转录病毒pLNCX/iNOS质粒。

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747447, encodeId=27cd1e4744788, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 19 07:08:30 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926876, encodeId=5daa19268e6f1, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Jul 17 03:08:30 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053209, encodeId=01842053209f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sun Aug 28 22:08:30 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-06-19 mjldent

    #转录#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1747447, encodeId=27cd1e4744788, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 19 07:08:30 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926876, encodeId=5daa19268e6f1, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Jul 17 03:08:30 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053209, encodeId=01842053209f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sun Aug 28 22:08:30 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-07-17 hxj0117

    #逆转录#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1747447, encodeId=27cd1e4744788, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Jun 19 07:08:30 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926876, encodeId=5daa19268e6f1, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Jul 17 03:08:30 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053209, encodeId=01842053209f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sun Aug 28 22:08:30 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-08-28 xiaogang317

    #逆转录病毒#

    0

相关威廉亚洲官网

溶瘤病毒疗法用于实体瘤治疗的新进展

溶瘤病毒疗法用于实体瘤治疗的新进展

一 氧化氮在肿瘤治疗中的研究进展

氧化氨(nitric de，N O ) 是新近发现的一种小分子气体，化学性质极为活泼， 具有显著的生物学活性。

ＴＲＡＦ４沉默对食管癌细胞 Ｅｃａ－１０９增殖、凋亡及细胞周期的影响

探讨小干扰 ＲＮＡ（ｓｉＲＮＡ）靶向沉默肿瘤坏死因子受体相关因子４（ＴＲＡＦ４）基因表达对人食管癌细胞 恶性行为的影响。

腹腔热灌注化疗并射频透热治疗恶性腹水的临床观察

观察腹腔热灌注化疗并射频局部透热治疗恶性腹水的临床效果 。

小剂量阿克拉霉素治疗骨髓增生异常综合征2例

骨髓增生异常综合征(MDS)中RAEB及 RAEB-T易向急性白血病转化，治疗上比较困难，williamhill asia 用小剂量阿克拉霉素(ACR)治疗3例，效果满意，报告如下。

A high serum-free fatty acid level is associated with cancer

Purpose The objectives of this work were to investigate whether the serum-free fatty acid (FFA) leve